-
Lifeist Sells Non-Core Swedish Subsidiary Findify For $4.45M To Maropost
Friday, May 27, 2022 - 12:49pm | 645Read More...Lifeist Wellness Inc. (OTCQB: NXTTF) (TSXV:LFST) (FRANKFURT:M5B) sold Findify AB, the company’s Swedish subsidiary that operates an AI-powered product search and discovery platform. Findify was acquired by Lifeist four years ago and successfully integrated technology to increase monetization...
-
Bitcoin Miner Genesis Digital Assets Raises $431M For Expansion
Wednesday, September 22, 2021 - 4:17pm | 335Read More...Major Bitcoin (CRYPTO: BTC) miner Genesis Digital Assets has raised $431 million in funding to expand its mining operations in the U.S. and Nordics. The new funding was led by Paradigm, which is one of the biggest cryptocurrency investment companies. Paradigm has...
-
Potash Corp. Shares Downgraded To Sell Amid 'Rally On Shaky Ground'
Tuesday, March 22, 2016 - 9:48am | 266Read More...Paradigm Capital has downgraded shares of Potash Corporation of Saskatchewan (USA) (NYSE: POT) to Sell from Hold, as prices remain depressed, oversupply remains a concern, farmer sentiment is low and there has not been a rally in grain prices. Potash shares are up 18 percent in the past month on a...
-
UPDATE: Paradigm Capital Downgrades BlackBerry Following Disappointing Q2 FY14 Results
Monday, September 23, 2013 - 11:32am | 218Read More...In a report published Monday, Paradigm Capital analyst Gabriel Leung downgraded the rating on BlackBerry Ltd. (NASDAQ: BBRY) from Speculative Buy to Hold, and lowered the price target from $15.00 to $10.50. In the report, Paradigm Capital noted, “BlackBerry announces much lower‐than‐expected...
-
UPDATE: Paradigm Capital Upgrades OpenText on Valuation, Multiple Catalysts
Monday, September 9, 2013 - 10:13am | 109Read More...In a report published Monday, Paradigm Capital analyst Gabriel Leung upgraded the rating on OpenText Corporation (NASDAQ: OTEX) from Hold to Buy, and raised the price target from $75.00 to $84.00. In the report, Paradigm Capital noted, “We are upgrading OpenText to a Buy (was Hold) due to...
-
US Stock Futures Up Ahead Of Consumer Credit Data
Monday, September 9, 2013 - 7:15am | 477Read More...Pre-open movers US stock futures rose in early pre-market trade, ahead of consumer credit data. Data on consumer credit for July will be released at 3:00 p.m. ET. Futures for the Dow Jones Industrial Average surged 36 points to 14,945.00, while the Standard & Poor's 500 index futures rose 4.50...
-
UPDATE: Paradigm Capital Downgrades OpenText on Possible Turbulence Ahead
Monday, June 24, 2013 - 7:55am | 122Read More...In a report published on Monday, Paradigm Capital analyst Gabriel Leung downgraded OpenText (NASDAQ: OTEX) from Buy to Hold and maintained a price target of $70. In the report, Paradigm Capital stated, "Valuation-wise, the stock is now trading at 12x forward 12-month EPS or 9.5x EV/EBITDA...
-
UPDATE: Paradigm Capital Upgrades BlackBerry to Speculative Buy on Q4 Results
Monday, April 1, 2013 - 10:10am | 193Read More...In a report published Monday, Paradigm Capital analyst Gabriel Leung upgraded the rating on BlackBerry (NASDAQ: BBRY) from Hold to Speculative Buy, and raised the price target from $16.00 to $19.00. In the report, Leung noted, “Overall, we view the Q4 results as being a net positive for BlackBerry...
-
UPDATE: Paradigm Capital Raises PT on Valeant Pharmaceuticals on Company Acquisition
Thursday, March 21, 2013 - 10:47am | 185Read More...Paradigm Capital analyst Alan Ridgeway published a report on Paradigm Capital (NYSE: VRX) that maintained its Buy rating and raised the price target from $83 to $35. Paradigm Capital reported that, “We believe this is a positive acquisition for Valeant, demonstrating that its strategy remains...
-
UPDATE: Paradigm Capital Lowers PT on IMRIS on Additions to Balance Sheet
Wednesday, March 13, 2013 - 1:21pm | 117Read More...In a report published Wednesday, Paradigm Capital analyst Alan Ridgeway reiterated his Buy rating on IMRIS (NASDAQ: IMRS), but slightly lowered his price target from $6.00 to $5.50. In the report, Ridgeway noted, “IM is a world leader in integrated image guided therapy solutions that allow for...
-
UPDATE: Paradigm Capital Downgrades Nordion to Hold on Diminished Outlook
Tuesday, January 29, 2013 - 10:04am | 105Read More...Paradigm Capital downgraded Nordion (NYSE: NDZ) from Buy to Hold and lowered the price target from $9.50 to $8.00. Paradigm Capital commented, "While the Q4 results were better than expected, we are reducing our price target and downgrading our recommendation to Hold (from Buy), as we believe the...
-
UPDATE: Paradigm Capital Upgrades Celestica to Buy, Raises PT
Wednesday, January 23, 2013 - 3:09pm | 143Read More...In a report published Wednesday, Paradigm Capital upgraded its rating on Celestica (NYSE: CLS) from Hold to Buy, and slightly raised its price target from $9.00 to $10.00. Paradigm Capital noted, “Overall, we believe the Q4 results and forward outlook essentially were in line with our expectations...
-
UPDATE: Paradigm Capital Downgrades Research In Motion to Hold on Service Model Changes
Friday, December 21, 2012 - 11:50am | 156Read More...Paradigm Capital reduced its rating on Research In Motion (NASDAQ: RIMM) from Buy to Hold but raised its price target from $14 to $14.50. Paradigm Capital noted, "While we are pleased to see the company execute on its operational restructuring plan (as evidenced by the better-than-expected...
-
UPDATE: Paradigm Capital Reiterates Buy Rating, Raises PT on Celestica
Wednesday, December 5, 2012 - 2:16pm | 77Read More...In a report published Wednesday, Paradigm Capital reiterated its Buy rating on Celestica (NYSE: CLS), and slightly raised its price target from $8.50 to $9.00. Paradigm Capital noted, “We view Celestica as an affordable way to gain broad technology exposure given its industry-low valuation....
-
UPDATE: Paradigm Capital Lowers PT to $67 on Valeant Pharmaceuticals on Raising Interest Cost
Wednesday, October 24, 2012 - 1:34pm | 107Read More...Paradigm Capital reiterated its Buy rating on Valeant Pharmaceuticals (NYSE: VRX) but lowered its price target from $70 to $67 ahead of the quarterly earnings release. Paradigm Capital commented, "We continue to hold a positive view toward Valeant's unique approach to running a specialty...
